Update on epidemiology and therapeutics for non-Hodgkin's lymphoma.

Julie Marie Vose, Brian C H Chiu, Bruce D. Cheson, Janet Dancey, John Wright

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

This chapter presents updated information on the trends and patterns of non-Hodgkin's lymphoma (NHL) diagnoses as well as new information on chemotherapeutic and immunotherapeutic options for NHL treatment. In Section I, Dr. Brian Chiu summarizes the current knowledge regarding the etiologic factors and patterns of NHL as well as suggests future epidemiologic studies based on these preliminary results. In Section II, Dr. Bruce Cheson and colleagues outline new chemotherapeutic and small molecule antineoplastic agents with unique mechanisms of action such as protease inhibitors, farnesyl transferase or histone deacetylase inhibitors, and antisense oligonucleotides. In Section III, Dr. Julie Vose reviews the anti-lymphoma effects of monoclonal antibodies, radioimmunoconjugates, idiotype vaccines, and immunologic enhancing adjuvants with respect to mechanisms of action, clinical trials, and their potential for patient therapy.

Fingerprint

Non-Hodgkin's Lymphoma
Epidemiology
Immunoconjugates
Immunologic Adjuvants
Histone Deacetylase Inhibitors
Antisense Oligonucleotides
Transferases
Protease Inhibitors
Antineoplastic Agents
Epidemiologic Studies
Lymphoma
Therapeutics
Vaccines
Monoclonal Antibodies
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. / Vose, Julie Marie; Chiu, Brian C H; Cheson, Bruce D.; Dancey, Janet; Wright, John.

In: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 01.01.2002, p. 241-262.

Research output: Contribution to journalReview article

@article{6c79bd353bca4e44bc3594f92cfa8a6a,
title = "Update on epidemiology and therapeutics for non-Hodgkin's lymphoma.",
abstract = "This chapter presents updated information on the trends and patterns of non-Hodgkin's lymphoma (NHL) diagnoses as well as new information on chemotherapeutic and immunotherapeutic options for NHL treatment. In Section I, Dr. Brian Chiu summarizes the current knowledge regarding the etiologic factors and patterns of NHL as well as suggests future epidemiologic studies based on these preliminary results. In Section II, Dr. Bruce Cheson and colleagues outline new chemotherapeutic and small molecule antineoplastic agents with unique mechanisms of action such as protease inhibitors, farnesyl transferase or histone deacetylase inhibitors, and antisense oligonucleotides. In Section III, Dr. Julie Vose reviews the anti-lymphoma effects of monoclonal antibodies, radioimmunoconjugates, idiotype vaccines, and immunologic enhancing adjuvants with respect to mechanisms of action, clinical trials, and their potential for patient therapy.",
author = "Vose, {Julie Marie} and Chiu, {Brian C H} and Cheson, {Bruce D.} and Janet Dancey and John Wright",
year = "2002",
month = "1",
day = "1",
doi = "10.1182/asheducation-2002.1.241",
language = "English (US)",
pages = "241--262",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Update on epidemiology and therapeutics for non-Hodgkin's lymphoma.

AU - Vose, Julie Marie

AU - Chiu, Brian C H

AU - Cheson, Bruce D.

AU - Dancey, Janet

AU - Wright, John

PY - 2002/1/1

Y1 - 2002/1/1

N2 - This chapter presents updated information on the trends and patterns of non-Hodgkin's lymphoma (NHL) diagnoses as well as new information on chemotherapeutic and immunotherapeutic options for NHL treatment. In Section I, Dr. Brian Chiu summarizes the current knowledge regarding the etiologic factors and patterns of NHL as well as suggests future epidemiologic studies based on these preliminary results. In Section II, Dr. Bruce Cheson and colleagues outline new chemotherapeutic and small molecule antineoplastic agents with unique mechanisms of action such as protease inhibitors, farnesyl transferase or histone deacetylase inhibitors, and antisense oligonucleotides. In Section III, Dr. Julie Vose reviews the anti-lymphoma effects of monoclonal antibodies, radioimmunoconjugates, idiotype vaccines, and immunologic enhancing adjuvants with respect to mechanisms of action, clinical trials, and their potential for patient therapy.

AB - This chapter presents updated information on the trends and patterns of non-Hodgkin's lymphoma (NHL) diagnoses as well as new information on chemotherapeutic and immunotherapeutic options for NHL treatment. In Section I, Dr. Brian Chiu summarizes the current knowledge regarding the etiologic factors and patterns of NHL as well as suggests future epidemiologic studies based on these preliminary results. In Section II, Dr. Bruce Cheson and colleagues outline new chemotherapeutic and small molecule antineoplastic agents with unique mechanisms of action such as protease inhibitors, farnesyl transferase or histone deacetylase inhibitors, and antisense oligonucleotides. In Section III, Dr. Julie Vose reviews the anti-lymphoma effects of monoclonal antibodies, radioimmunoconjugates, idiotype vaccines, and immunologic enhancing adjuvants with respect to mechanisms of action, clinical trials, and their potential for patient therapy.

UR - http://www.scopus.com/inward/record.url?scp=0042990723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042990723&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2002.1.241

DO - 10.1182/asheducation-2002.1.241

M3 - Review article

SP - 241

EP - 262

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -